I 
112TH CONGRESS 
1ST SESSION H. R. 1845 
To provide for a study on issues relating to access to intravenous immune 
globulin (IVIG) for Medicare beneficiaries in all care settings and a 
demonstration project to examine the benefits of providing coverage and 
payment for items and services necessary to administer IVIG in the 
home. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 11, 2011 
Mr. BRADY of Texas (for himself, Ms. MATSUI, Mr. BURGESS, Mr. SARBANES, 
Mr. PAUL, Mr. VAN HOLLEN, Mr. TIBERI, Mr. RUPPERSBERGER, Mrs. 
BLACKBURN, Mr. SCHIFF, Ms. JENKINS, Mr. KIND, Ms. FUDGE, Ms. 
RICHARDSON, and Mr. RUSH) introduced the following bill; which was re-
ferred to the Committee on Ways and Means, and in addition to the 
Committee on Energy and Commerce, for a period to be subsequently de-
termined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
A BILL 
To provide for a study on issues relating to access to intra-
venous immune globulin (IVIG) for Medicare bene-
ficiaries in all care settings and a demonstration project 
to examine the benefits of providing coverage and pay-
ment for items and services necessary to administer IVIG 
in the home. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Mar 15 2010 
04:11 May 17, 2011
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1845.IH
H1845
jbell on DSKDVH8Z91PROD with BILLS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Medicare IVIG Access 
Act’’. 
SEC. 2. MEDICARE PATIENT IVIG ACCESS DEMONSTRATION 
PROJECT. 
(a) ESTABLISHMENT.—The Secretary shall establish 
and implement a demonstration project under title XVIII 
of the Social Security Act to evaluate the benefits of pro-
viding payment for items and services needed for the ad-
ministration, within the homes of Medicare beneficiaries, 
of intravenous immune globin for the treatment of pri-
mary immune deficiency diseases. 
(b) DURATION AND SCOPE.— 
(1) DURATION.—Beginning not later than 6 
months after the date of enactment of this Act, the 
Secretary shall conduct the demonstration project 
for a period of 3 years. 
(2) SCOPE.—The Secretary shall enroll not 
greater than 4,000 Medicare beneficiaries who have 
been diagnosed with primary immunodeficiency dis-
ease for participation in the demonstration project. 
A Medicare beneficiary may participate in the dem-
onstration project on a voluntary basis and may ter-
minate participation at any time. 
(c) REIMBURSEMENT.—The Secretary shall establish 
an hourly rate for payment for items and services needed 
VerDate Mar 15 2010 
04:11 May 17, 2011
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1845.IH
H1845
jbell on DSKDVH8Z91PROD with BILLS
for the administration of intravenous immune globin based 
on the low-utilization payment adjustment under the pro-
spective payment system for home health services estab-
lished under section 1895 of the Social Security Act (42 
U.S.C. 1395fff). 
(d) STUDY AND REPORT TO CONGRESS.— 
(1) INTERIM EVALUATION AND REPORT.—Not 
later than 24 months after the date of enactment of 
this Act, the Secretary shall submit to Congress a 
report that contains the following: 
(A) An interim evaluation of the impact of 
the demonstration project on access for Medi-
care beneficiaries to items and services needed 
for the administration of intravenous immune 
globin within the home. 
(B) An analysis of the appropriateness of 
implementing a new methodology for payment 
for intravenous immune globulins in all care 
settings under part B of title XVIII of the So-
cial Security Act (42 U.S.C. 1395k et seq.). 
(C) An analysis of the feasability of reduc-
ing the lag time with respect to data used to 
determine the average sales price under section 
1847A of the Social Security Act (42 U.S.C. 
1395w–3a). 
VerDate Mar 15 2010 
04:11 May 17, 2011
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1845.IH
H1845
jbell on DSKDVH8Z91PROD with BILLS
(D) An update to the report entitled 
‘‘Analysis of Supply, Distribution, Demand, and 
Access Issues Associated with Immune Globulin 
Intravenous (IGIV)’’, issued in February 2007 
by the Office of the Assistant Secretary for 
Planning and Evaluation of the Department of 
Health and Human Services. 
(2) FINAL
EVALUATION
AND
REPORT.—Not 
later than July 1, 2015, the Secretary shall submit 
to Congress a report that contains a final evaluation 
of the impact of the demonstration project on access 
for Medicare beneficiaries to items and services 
needed for the administration of intravenous im-
mune globin within the home. 
(e) OFFSET.— 
(1) IN GENERAL.—Section 1861(n) of the So-
cial Security Act (42 U.S.C. 1395x(n)) is amended 
by adding at the end the following: ‘‘Such term in-
cludes disposable drug delivery systems, including 
elastomeric infusion pumps, for the treatment of 
colorectal cancer.’’. 
(2) EFFECTIVE DATE.—The amendment made 
by paragraph (1) shall apply to items furnished on 
or after the date of enactment of this Act. 
(f) DEFINITIONS.—In this Act: 
VerDate Mar 15 2010 
04:11 May 17, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1845.IH
H1845
jbell on DSKDVH8Z91PROD with BILLS
(1) DEMONSTRATION
PROJECT.—The term 
‘‘demonstration project’’ means the demonstration 
project conducted under this Act. 
(2) 
MEDICARE
BENEFICIARY.—The 
term 
‘‘Medicare beneficiary’’ means an individual who is 
entitled to, or enrolled for, benefits under part A of 
title XVIII of the Social Security Act or enrolled for 
benefits under part B of such title. 
(3) SECRETARY.—The term ‘‘Secretary’’ means 
the Secretary of Health and Human Services. 
Æ 
VerDate Mar 15 2010 
04:11 May 17, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H1845.IH
H1845
jbell on DSKDVH8Z91PROD with BILLS